U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06823713) titled 'RTX001 Autologous Engineered Macrophages for Liver Cirrhosis' on Nov. 06, 2024.
Brief Summary: The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.
Study Start Date: Oct. 15, 2024
Study Type: INTERVENTIONAL
Condition:
End-stage Liver Disease (ESLD)
Cirrhosis, Liver
Cirrhosis, Decompensated
Liver Diseases
Fibrosis and Cirrhosis of Liver
Decompensated Liver Cirrhosis
Decompensated Cirrhosis
Steatotic Liver Disease
Int...